Spruce Biosciences (SPRB) Current Leases (2020 - 2024)
Spruce Biosciences (SPRB) posted quarterly Current Leases of $275000.0 for Q3 2024, up 12.7% year-over-year from $244000.0 in Q4 2023, and up 3.0% quarter-over-quarter from $267000.0 in Q2 2024.
Spruce Biosciences (SPRB) Current Leases (2020 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported Current Leases for 5 consecutive years, with $275000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Current Leases rose 12.7% year-over-year to $275000.0; the TTM figure through Sep 2024 stood at $275000.0 (up 12.7% YoY), while the FY2023 annual figure was $251000.0, up 80.58% from the prior year.
- Current Leases grew to $275000.0 in Q3 2024 per SPRB's latest filing, from $267000.0 in the prior quarter.
- Across five years, Current Leases topped out at $380000.0 in Q2 2022 and bottomed at $139000.0 in Q4 2022.
- Historically, Current Leases has averaged $285466.7 across 5 years, with a median of $267000.0 in 2024.
- Annual changes were most pronounced in 2022 — Current Leases plunged 61.39% — and 2023, when it surged 80.58%.
- Spruce Biosciences' Current Leases stood at $249000.0 in 2020, then jumped by 44.58% to $360000.0 in 2021, then slumped by 61.39% to $139000.0 in 2022, then surged by 80.58% to $251000.0 in 2023, then rose by 9.56% to $275000.0 in 2024.
- Business Quant data shows SPRB's Current Leases at $275000.0 in Q3 2024, $267000.0 in Q2 2024, and $259000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Spruce Biosciences | 123.45 Mn | 123.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 267,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 251,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Jun 30, 2023 | 236,000.00 |
| Mar 31, 2023 | 229,000.00 |
| Dec 31, 2022 | 139,000.00 |
| Jun 30, 2022 | 380,000.00 |
| Mar 31, 2022 | 370,000.00 |
| Dec 31, 2021 | 360,000.00 |
| Sep 30, 2021 | 350,000.00 |
| Jun 30, 2021 | 341,000.00 |
| Mar 31, 2021 | 332,000.00 |
| Dec 31, 2020 | 249,000.00 |